WS Investor
29 Sep 2026, 19:51
Dexcom Report Highlights Large Untapped CGM Opportunity in Type 2 Diabetes
Dexcom released its 2026 State of Type 2 Report at the EASD meeting, highlighting what the company sees as a significant gap between the clinical value of continuous glucose monitoring and its current adoption among people with Type 2 diabetes.
The report surveyed more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries. Dexcom identified three main barriers to broader CGM use: health literacy, technology literacy and access.
Healthcare professionals expressed strong support for CGM. According to the survey, 89% said CGM helps them assess treatment adherence between appointments. Among current users, more than half said they followed their treatment plan more closely after adopting CGM.
Access remains a major constraint. About 55% of people with Type 2 diabetes reported limited knowledge of CGM, while reimbursement and coverage challenges were cited by 90% of U.S. healthcare professionals and 53% of those in the other surveyed countries.
The report also pointed to a growing link between GLP-1 therapies and CGM use. Among Type 2 patients using GLP-1 drugs, 58% also used CGM, compared with just 27% of non-insulin users overall. Dexcom said this suggests further room for adoption as GLP-1 use expands.
Separately, Dexcom announced a partnership with Team Novo Nordisk to become the professional cycling team’s official continuous glucose monitoring partner, supporting research, education and awareness in Type 1 diabetes.
Dexcom released its 2026 State of Type 2 Report at the EASD meeting, highlighting what the company sees as a significant gap between the clinical value of continuous glucose monitoring and its current adoption among people with Type 2 diabetes.
The report surveyed more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries. Dexcom identified three main barriers to broader CGM use: health literacy, technology literacy and access.
Healthcare professionals expressed strong support for CGM. According to the survey, 89% said CGM helps them assess treatment adherence between appointments. Among current users, more than half said they followed their treatment plan more closely after adopting CGM.
Access remains a major constraint. About 55% of people with Type 2 diabetes reported limited knowledge of CGM, while reimbursement and coverage challenges were cited by 90% of U.S. healthcare professionals and 53% of those in the other surveyed countries.
The report also pointed to a growing link between GLP-1 therapies and CGM use. Among Type 2 patients using GLP-1 drugs, 58% also used CGM, compared with just 27% of non-insulin users overall. Dexcom said this suggests further room for adoption as GLP-1 use expands.
Separately, Dexcom announced a partnership with Team Novo Nordisk to become the professional cycling team’s official continuous glucose monitoring partner, supporting research, education and awareness in Type 1 diabetes.
